Gold and silver prices held steady driven mainly by Federal Reserve signals rather than geopolitical events. Strong inflation data in September and October increased expectations of further Fed rate hikes, causing the dollar to ease and bond yields to fall. Gold benefited from robust central bank buying, especially by China, and record ETF inflows, while silver faced tighter supply and structural deficits despite rising demand in tech sectors. The Fed's upcoming meeting and inflation reports will be key to future price movements, with technical analysis showing gold and silver poised for potential gains if key resistance levels are broken.
Gold and silver price forecasts provide context for market activity on Pluang. For readers following US stocks, here is Pluang's market snapshot as of Oct 16, 2026 14:51 WIB: out of 150 priced US stocks, 95 rose and 50 fell today. Notable movers include Nokia Corp at USD 9.69 with a 1-day change of +1.25% and a typical hold time of 65 days, Salesforce Inc at USD 249.78 up +1.23%, and Snowflake Inc at USD 339.00 up +1.17%.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
